Stalwart Advisors

Suven Pharma (CRAMS) to List on 9th March

Suven Pharmaceuticals, the demerged CRAMS business of Suven Life Sciences is scheduled to list on Stock Exchanges tomorrow, 9th March 2020.

Suven Pharmaceuticals shares should reflect in your demat account in same quantity as you held in Suven Life Sciences as on record date. If not, you must contact your broker/DP.

The investment thesis is intact, and we continue to like the business quality and growth prospects.

The rating (buy or hold) will be based on the valuation it lists at and we will notify regarding the same. For now, keep holding the existing quantity.

Source: https://www.bseindia.com/markets/MarketInfo/DispNewNoticesCirculars.aspx?page=20200305-52


Privacy policy
Mobile Analytics
Exact weightage will depend on each subscriber’s risk appetite & comfort. However, as a thumb rule, any position size under 3% is little insignificant to move returns at portfolio level whereas beyond 10% it gets riskier from a concentration standpoint. Accordingly, low could indicate 3-4% weightage, medium 5-7% and high 8-10%.
Structural are those portfolio businesses where earnings are relatively stable (less volatility) and further are expected to rise in a steady fashion. Cyclicals are businesses which experience periods of upcycle followed by downcycle and have large variation in their reported earnings based on industry demand and supply. The mix between the two depends on available opportunities and respective valuation of the two pockets.